Compare VFF & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFF | AURA |
|---|---|---|
| Founded | 1989 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.2M | 355.0M |
| IPO Year | N/A | 2021 |
| Metric | VFF | AURA |
|---|---|---|
| Price | $3.23 | $5.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | ★ 1.1M | 185.0K |
| Earning Date | 03-12-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $351,979,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.43 | N/A |
| P/E Ratio | $17.05 | ★ N/A |
| Revenue Growth | ★ 56.61 | N/A |
| 52 Week Low | $0.45 | $4.35 |
| 52 Week High | $4.99 | $8.27 |
| Indicator | VFF | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 51.12 |
| Support Level | $2.98 | $5.33 |
| Resistance Level | $3.39 | $6.15 |
| Average True Range (ATR) | 0.16 | 0.34 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 43.33 | 54.66 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Leli . The company makes majority of its revenue from the Produce segment.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.